$43.13 Million Strategic Investment from Dangdai International Group
Co., Limited

Cellular Biomedicine Group Announces a
$43.13 Million Strategic Investment from Dangdai International Group
Co., Limited, a wholly owned Hong Kong Subsidiary of Wuhan Dangdai
Science & Technology Industries Group Inc.

SHANGHAI, China and CUPERTINO, Calif., February 4, 2016
/GlobeNewswire/ — Cellular Biomedicine Group Inc. (NASDAQ: CBMG)
(“CBMG” or the “Company”), a biomedicine firm engaged in the
development of effective stem cell therapies for degenerative
diseases and immunotherapies for cancer, today announced Wuhan
Dangdai Science & Technology Industries Group Inc. (“DANGDAI”)
has agreed to invest $43.13 million in 2.27 million shares of the
Company’s common stock, a 19.4% stake investment, at $19 per share,
representing a premium of 10.4% over yesterday’s closing price.
Based in Wuhan, China, DANGDAI is a conglomerate with a substantial
medical and pharmaceutical portfolio in China.

The
Company has received $5 million and issued 263,158 shares to
DANGDAI. Hubei Province Department of Commerce is processing
DANGDAI’s remaining funding of $38.13 million as an outbound foreign
direct investment. The Company expects funding completion before
April 15, 2016. As part of the consideration, CBMG has extended an
invitation to DANGDAI to occupy an observer seat on the Company’s
Board of Directors.

“We appreciate the huge vote of
confidence from DANGDAI. We are delighted that such an astute,
established conglomerate with a major pharmaceutical presence is
making this strategic investment in CBMG. Their pharmaceutical
portfolio company has a large direct sales force in China with
access to thousands of hospitals. The funding will augment resources
for our long-term clinical trials in stem cell indications and
multiple T-cell Chimeric Antigen Receptor (“CAR-T”) trials in liquid
and solid tumor cancers,” said Tony (Bizuo) Liu, incoming Chief
Executive Officer (current CFO) of CBMG.

“We are pleased
about our strategic investment in CBMG. This is an innovative
company with technological sophistication and a seasoned management
team who seek to turn translational medicine into clinical benefits.
With their strong China presence and budding foray into the U.S., we
are confident that the team will monetize their translational
medicine pipeline to improve patients’ quality of life. I am
confidant CBMG will emerge as a biomedicine leader,” commented Zhou
Han Sheng, Chief Executive Officer of DANGDAI.

About
Cellular Biomedicine Group
Cellular Biomedicine Group, Inc.
develops proprietary cell therapies for the treatment of certain
degenerative and cancerous diseases. Our developmental stem cell
and Immuno-Oncology projects are the result of research and
development by scientists and doctors from China and the United
States. Our GMP facilities in China, consisting of nine independent
cell production lines, are designed, certified and managed according
to U.S. standards. To learn more about CBMG, please visit:
www.cellbiomedgroup.com

About Wuhan Dangdai Science
& Technology Industries Group Inc.
Founded in 1988, Wuhan
Dangdai Science & Technology Industries Group Inc. (“DANGDAI”)
is a China based privately held conglomerate managed by a savvy
leadership team. DANGDAI’s business ethics focus is on innovation,
pragmatism, transparency, governance, collaboration, and prudence;
and has a strong sense of social responsibility. Its portfolio
companies are comprised of several Chinese publicly listed entities
and private companies in North America and Africa. DANGDAI’s
diverse enterprise includes biopharmaceuticals, media,
entertainment, real estate development, tourism, agriculture,
textile and financial services.

Forward-Looking
Statements
Statements in this press release relating to plans,
strategies, trends, specific activities or investments, and other
statements that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include risks inherent
in doing business, trends affecting the global economy, including the
devaluation of the RMB by China in August 2015 and other risks
detailed from time to time in CBMG’s reports filed with the
Securities and Exchange Commission, quarterly reports on form 10-Q,
current reports on form 8-K and annual reports on form 10-K.
Forward-looking statements may be identified by terms such as “may,”
“will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or
“continue,” or similar terms or the negative of these terms. Although
CBMG believes the expectations reflected in the forward-looking
statements are reasonable, they cannot guarantee that future results,
levels of activity, performance or achievements will be obtained.
CBMG does not have any obligation to update these forward-looking
statements other than as required by law.

Contacts:

人福医药布局CAR-T，Cellular Biomedicine 集团融资4300万美元。

西比曼生物科技（Cellular Biomedicine Group）宣布，获得武汉当代科技产业集团（Wuhan Dangdai
Science & Technology Industries Group）4310万美元股权投资。这笔投资相比于收盘价有10%的溢价，武汉当代持有公司19.4%的股票。这笔资金将被用于增强公司的资源，以应对干细胞疗法及针对多种肿瘤的CAR-T疗法的长期临床试验。截止到去年9月底武汉当代科技产业集团股份有限公司持有人福医药11.976%的股份，为流通的第一大股东。

方润医疗完成6000万元人民币A轮融资，红杉资本和毓承资本投资

2016-01-20 10:58·　 新芽NewSeed　 　

摘要沈南鹏表示：“中国未来在医疗健康这一热点领域的市场空间巨大，发展速度迅猛。随着消费者需求多样性的增加，行业内变化正催生着更为广泛的创业机会，很多细分领域都可能跑出大公司。”

　　近期，方润医疗器械科技（上海）有限公司（“方润医疗”）宣布成功完成6000万元人民币A轮融资，本次融资由红杉资本中国基金（Sequoia Capital China)和毓承资本（WuXi Healthcare Ventures)联合投资。该融资的成功完成将提升方润医疗在微创治疗领域的新产品开发，加快全球市场开拓以及优化公司整体架构。

　　公司创始人秦杰先生表示，消融技术是微创手术领域中应用最广泛，使用量最多的技术。经过多年的努力，目前国产的消融产品已经在肿瘤等领域日渐成熟，逐步取代了进口，给国内肿瘤患者带来了福音。等离子消融技术是近年来国际上开发出来的新一代的消融技术，其低温的特征使其在关节、脊柱和耳鼻喉的应用中优势特别显著，成为运动医学中微创手术的金标准。随着全球人口的老龄化以及健康运动的生活方式，运动医学已经逐渐成为一个主流的医学科目，社会需求巨大。方润作为国内等离子消融技术及相关运动医学技术的先驱者和领导者，很高兴能和国际一流的投资机构红杉资本中国基金（Sequoia Capital China)和毓承资本（WuXi Healthcare Ventures)合作。期待公司在运动医学的基础上进一步发展，成为多种临床应用的平台型公司，造福国内广大患者。

　　红杉资本全球执行合伙人沈南鹏表示：“中国未来在医疗健康这一热点领域的市场空间巨大，发展速度迅猛。随着消费者需求多样性的增加，行业内变化正催生着更为广泛的创业机会，很多细分领域都可能跑出大公司。红杉资本中国基金始终致力于在医疗健康领域内积极投资，帮助优秀的医疗科技创新企业发挥更大价值。”

　　药明康德董事长李革博士表示：”毓承资本的核心理念就是要发掘、投入并发展国内外最领先的医疗健康技术创新企业。此次与秦总和方润合作，就是看重方润作为国内运动医疗微创领域的领跑者，利用自身的创新技术和卓越管理，可以通过自主研发和行业整合早日打造出全面的运动医疗诊疗平台，服务更多的医生和病患。”

　　红杉资本中国基金合伙人陈鹏辉表示：“我们非常高兴能和秦总以及方润医疗这样优秀的企业合作，我们看好运动医学在中国的巨大前景，也看好方润在微创治疗技术领域的长期积累。我们希望能够在国内外并购和新产品引进等方面帮助方润更快更好的发展”

　　毓承资本合伙人邢菲博士表示：”近年来，运动医学市场高速发展，而微创介入作为最领先的细分领域，更以几何级数增长。方润公司是国内该领域的领导者，拥有超一流团队和国际领先核心专利技术。除了资金，毓承资本更希望借助我们对前沿医疗技术的理解和全球化的网络资源，与方润强强联手，为方润迅速实现运动医学平台化战略助一臂之力。”

　　方润医疗目前共获得CFDA注册5项，国家专利10项，上海市高新技术企业，并获得TüV产品认证及ISO 13485质量体系认证；多项在研产品承担了科技部、科技支撑计划等重大科研项目；自2009年成立以来，伴随研发水平提高以及生产技术变革，公司产品涉及运动医学、脊柱、耳鼻喉等领域。公司聚集了机械、电子、高分子、精密加工、临床医学等专业人才，拥有一批在产品设计、质量控制、临床验证、市场开拓等经验丰富的人才队伍。目前方润医疗的低温等离子微创治疗技术属于国际领先水平，并多次参与国内等离子行业标准的起草与制订。

　　方润医疗未来将不断致力于自主创新类产品的研制，不断开发高值微创治疗产品，为广大医护工作者及患者提供更好的医疗产品与技术，为医疗健康事业作出最大的努力，公司将进一步提升产品在各个领域的知名度与影响力。

　　红杉资本自1972年在美国成立以来，作为第一家机构投资人投资了众多创新公司。专注于来自TMT、消费与现代服务、医疗健康、新能源与清洁技术四大领域，从初创期到成长期的优秀创业项目。十年来，红杉在中国投资了约 300 家具有鲜明技术和创新商业模式、具备高成长性和高回报潜力的成长型公司。

　　毓承资本专注于投资发展全球最优秀创新医疗公司，凭借丰富运营经验、战略支持、资本以及长期投资耐心，寻找、孵化、助力全球生命科学及医疗企业的发展。